10-QPeriod: Q2 FY2024

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2024

Filed July 25, 2024For Securities:DXCM

Summary

DexCom, Inc. reported a strong second quarter for 2024, demonstrating robust growth and profitability. Revenue increased by 15% year-over-year to $1.004 billion, driven by sustained demand for their continuous glucose monitoring (CGM) systems. Gross profit also grew by 15% to $626.7 million, indicating effective cost management alongside sales expansion. The company achieved significant operating income growth of 23%, reaching $158.0 million, and net income surged by 24% to $143.5 million, highlighting operational efficiency and strong earnings power. The company's balance sheet remains healthy, with cash, cash equivalents, and short-term marketable securities totaling $3.12 billion, providing substantial liquidity. Cash flow from operations was particularly strong, showing a 47% increase year-over-year for the quarter, underscoring the company's ability to generate substantial cash from its core business activities. Furthermore, DexCom announced a new $750 million share repurchase program, signaling confidence in its financial position and commitment to returning value to shareholders.

Financial Highlights

51 data points
Beta

Revenue

$1.00B

62.4% Gross Margin

Net Income

$143.50M

14.3% Net Margin

EPS (Diluted)

$0.35

Total Assets

$6.80B

Cash & Equivalents

$939.20M

Free Cash Flow

$213.30M

Financial Statements
Beta
Revenue$1.00B
Cost of Revenue$377.60M
Gross Profit$626.70M
R&D Expenses$136.00M
SG&A Expenses$332.70M
Operating Expenses$468.70M
Operating Income$158.00M
Interest Expense$3.80M
Net Income$143.50M
EPS (Basic)$0.36
EPS (Diluted)$0.35
Shares Outstanding (Basic)399.20M
Shares Outstanding (Diluted)416.80M

Key Highlights

  • 1Revenue increased by 15% to $1.004 billion for the three months ended June 30, 2024, compared to $871.3 million in the prior year period.
  • 2Net income grew by 24% to $143.5 million for the three months ended June 30, 2024, up from $115.9 million in the prior year period.
  • 3Diluted net income per share rose to $0.35 from $0.28 in the same period last year, a 25% increase.
  • 4Operating income saw a substantial increase of 23% year-over-year, reaching $158.0 million.
  • 5Cash flow from operating activities for the six months ended June 30, 2024, was $488.6 million, an increase from $345.7 million in the prior year period.
  • 6The company ended the quarter with $3.12 billion in cash, cash equivalents, and short-term marketable securities, indicating strong liquidity.
  • 7DexCom announced a new $750 million share repurchase program authorized in July 2024.

Frequently Asked Questions

DexCom reported a 15% increase in revenue for the three months ended June 30, 2024, reaching $1.004 billion, up from $871.3 million in the same period last year. For the six-month period, revenue grew by 19% to $1.925 billion.

Profitability showed strong improvement. Net income for the second quarter of 2024 increased by 24% to $143.5 million, with diluted earnings per share rising 25% to $0.35. Operating income also grew significantly by 23% to $158.0 million.

DexCom maintains a strong liquidity position, ending the quarter with $3.12 billion in cash, cash equivalents, and short-term marketable securities. Operating cash flow was robust, generating $488.6 million for the six-month period, demonstrating the company's ability to fund its operations and growth.

DexCom is involved in ongoing patent litigation with Abbott Diabetes Care. While a jury returned a mixed verdict in one U.S. case, Dexcom is challenging the finding of infringement and believes it is not probable that an unfavorable outcome leading to a material loss will occur. However, due to the complexity and ongoing nature of multiple international and U.S. patent disputes, the ultimate outcome of all litigation matters remains uncertain.

In July 2024, DexCom's Board of Directors authorized a new share repurchase program of up to $750 million, indicating a commitment to returning capital to shareholders. The company continues to invest in research and development for future product generations and expanding its market reach, including for non-insulin dependent Type 2 diabetes patients.